114 results
Keyword Triumeq Remove keyword
-
List item
Summary of opinion: Triumeq
abacavir sulfate / dolutegravir sodium / lamivudine, opinion date: 15/12/2022, Positive, Last updated: 16/12/2022Triumeq: Pending EC decision … opinion1 (post authorisation) Triumeq dolutegravir / abacavir … for the medicinal product Triumeq. The marketing authorisation … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Triumeq, dolutegravir, abacavir, lamivudine
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001219-PIP01-11-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Dispersible tablet
Decision date: 17/03/2021, Last updated: 23/11/2021, Compliance check: XInvented name Triumeq Active substance dolutegravir … abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M05 … abacavir / lamivudine (Triumeq), (EMEA-001219-PIP01-11-M05 … -
List item
Human medicine European public assessment report (EPAR): Triumeq
dolutegravir sodium, lamivudine, abacavir (as sulfate), HIV Infections
Date of authorisation: 31/08/2014, Revision: 30, Authorised, Last updated: 08/11/2022Triumeq Blood-Borne Infections Communicable … Triumeq … risk management plan for TRIUMEQ This is a summary of the … -
List item
Press release: New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir
PRAC, Last updated: 18/05/2018lamivudine and abacavir as Triumeq. Further information on these … lamivudine and abacavir as Triumeq. Further information on these … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 June 2014
Last updated: 27/06/2014Triumeq … -
List item
Press release: Updated advice on body fat changes and lactic acidosis with HIV medicines
CHMP, Last updated: 23/10/2015Stribild, Sustiva, Telzir, Triumeq, Trizivir, Truvada, Viramune … Lamivudine ViiV, Stribild, Triumeq, Truvada, Viread and Ziagen … Stribild, Sustiva, Telzir, Triumeq, Trizivir, Truvada, Viramune … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
CHMP, Last updated: 16/12/2022Triumeq … -
List item
National expert: Pere Domingo, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 82.83 KB | PDF
- Curriculum Vitae - 135.21 KB | PDF
Healthcare Kivexa, Tivicay, Triumeq, Dovato HIV infection … -
List item
National expert: Leonard van den Berg, European Medicines Agency (updated)
- Declaration of interests - 84.99 KB | PDF
- Curriculum Vitae - 28.38 KB | PDF
initiated trial to investigate Triumeq 2.11 Committee for Advanced … -
List item
Human medicine European public assessment report (EPAR): Juluca (updated)
dolutegravir sodium, rilpivirine hydrochloride, HIV Infections
Date of authorisation: 16/05/2018, Revision: 14, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Dovato
dolutegravir sodium, lamivudine, HIV Infections
Date of authorisation: 10/06/2022, Revision: 12, Authorised, Last updated: 08/11/2022 -
List item
Human medicine European public assessment report (EPAR): Trizivir
abacavir (as sulfate), lamivudine, zidovudine, HIV Infections
Date of authorisation: 27/12/2000, Revision: 42, Authorised, Last updated: 27/09/2022regimen. (e.g. Kivexa, Ziagen, Triumeq) • Trizivir must be stopped … abacavir (e.g. Kivexa, Ziagen, Triumeq) must never be re- initiated … -
List item
Human medicine European public assessment report (EPAR): Ziagen
abacavir, HIV Infections
Date of authorisation: 08/07/1999, Revision: 46, Authorised, Last updated: 29/08/2022 -
List item
Human medicine European public assessment report (EPAR): Combivir
lamivudine, zidovudine, HIV Infections
Date of authorisation: 18/03/1998, Revision: 37, Authorised, Last updated: 29/08/2022 -
List item
Human medicine European public assessment report (EPAR): Tivicay
dolutegravir, HIV Infections
Date of authorisation: 16/01/2014, Revision: 32, Authorised, Last updated: 08/11/2022 -
List item
Human medicine European public assessment report (EPAR): Kivexa
abacavir, lamivudine, HIV Infections
Date of authorisation: 16/12/2004, Revision: 36, Authorised, Last updated: 23/08/2022 -
List item
Human medicine European public assessment report (EPAR): Epivir
lamivudine, HIV Infections
Date of authorisation: 08/08/1996, Revision: 50, Authorised, Last updated: 29/08/2022 -
List item
Human medicine European public assessment report (EPAR): Rekambys
rilpivirine, HIV Infections
Date of authorisation: 17/12/2020,
, Revision: 7, Authorised, Last updated: 23/11/2022
-
List item
Human medicine European public assessment report (EPAR): Adempas
riociguat, Hypertension, Pulmonary
Date of authorisation: 27/03/2014, Revision: 12, Authorised, Last updated: 14/06/2022 -
List item
Human medicine European public assessment report (EPAR): Vocabria (updated)
Cabotegavir sodium, Cabotegravir, HIV Infections
Date of authorisation: 17/12/2020,, Revision: 8, Authorised, Last updated: 12/01/2023
-
List item
Human medicine European public assessment report (EPAR): Genvoya
elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections
Date of authorisation: 19/11/2015, Revision: 27, Authorised, Last updated: 28/11/2022 -
List item
Opinion on medicine for use outside EU: Lamivudine ViiV
lamivudine, HIV Infections, ATC code: J05AF05 Opinion number: H/W/673, Withdrawn opinion Opinion date: 17/11/2005, Last updated: 05/07/2018 -
List item
Opinion on medicine for use outside EU: Lamivudine / Zidovudine ViiV (previously Lamivudine / Zidovudine GSK)
lamivudine, zidovudine, HIV Infections, ATC code: J05AR01 Opinion number: H/W/672, Withdrawn opinion Opinion date: 17/11/2005, Last updated: 05/07/2018 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 27/01/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 18/01/2023